<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html dir="ltr" xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml">
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>

<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<!-- 
	This website is powered by TYPO3 - inspiring people to share!
	TYPO3 is a free open source Content Management Framework initially created by Kasper Skaarhoj and licensed under GNU/GPL.
	TYPO3 is copyright 1998-2015 of Kasper Skaarhoj. Extensions are copyright of their respective owners.
	Information and contribution at http://typo3.org/
-->



<title>INHN: Bulletin 34 : Starting Up (Volume One): 2. Psychiatry</title>
<meta name="generator" content="TYPO3 4.5 CMS" />

<link rel="stylesheet" type="text/css" href="IMAGES/STYLESHEET_9B1E31873F2366.CSS?1645000983" media="all" />



<script src="IMAGES/JAVASCRIPT_93077BB238F3E1.JS?1645000982" type="text/javascript"></script>


<link href="IMAGES/LAYOUT_3COL_STANDARD.CSS" rel="stylesheet" type="text/css" /><!--[if lte IE 7]><link href="fileadmin/styles/patches/../01_layouts_basics/css/patches/patch_3col_standard.css" rel="stylesheet" type="text/css" /><![endif]-->
<meta name="DC.title" content="Bulletin 34 : Starting Up (Volume One): 2. Psychiatry" />
<meta name="description" content="INHN" />
<meta name="DC.Description" content="INHN" />
<meta name="keywords" content="International Network for the History of Neuropsychopharmacology" />
<meta name="DC.Subject" content="International Network for the History of Neuropsychopharmacology" />
<meta name="copyright" content="Copyright INHN 2012-14" />
<meta name="DC.Rights" content="Copyright INHN 2012-14" />
<meta http-equiv="content-language" content="en" />
<meta name="DC.Language" scheme="NISOZ39.50" content="en" />
<link rev="made" href="mailto:inhn@inhn.org" />
<meta http-equiv="reply-to" content="inhn@inhn.org" />
<meta name="author" content="Gregers Wegener" />
<meta name="DC.Creator" content="Gregers Wegener" />
<meta name="rating" content="General" />
<meta name="date" content="2019-03-12T16:50:54+00:00" />
<meta name="DC.date" content="2019-03-12T16:50:54+00:00" />
<meta name="robots" content="index,follow" />
<meta name="revisit-after" content="7" />
<link rel="start" href="INDEX681A.HTM?id=1" />
<link rel="up" href="INDEX768D.HTM?id=2359" />
<link rel="next" href="INDEX22AE.HTM?id=2656" />
<link rel="prev" href="INDEX6B55.HTM?id=2638" />
<link rel="canonical" href="INDEXEDEF.HTM?id=2647" />



</head>
<body id="pageUID-2647">


<div id="page_margins">
	<div id="page">
		<div id="header"><div class="tx-macinasearchbox-pi1">
		
<form action="https://inhn.org/index.php?id=5&amp;L=0" method="post" name="searchform" id="searchform">
<input name="tx_indexedsearch[sword]" type="text" value="Enter search word..." onclick="this.value=''" onblur="this.value='Enter search word...'" /><br />
<input type="hidden" name="tx_indexedsearch[_sections]" value="0" />
<input type="hidden" name="tx_indexedsearch[pointer]" value="0" />
<input type="hidden" name="tx_indexedsearch[ext]" value="0" />
<input type="hidden" name="tx_indexedsearch[lang]" value="0" />
</form>

	</div>
	<div id="topnav"><a class="skip" href="#navigation" title="Direkt zur Navigation springen">Zur Navigation springen</a><span class="hideme">.</span><a class="skip" href="#content" title="Direkt zum Content springen">Zum Content springen</a><span class="hideme">.</span><a href="INDEX3A9F.HTM?id=6" target="_self">Sitemap</a>&nbsp;&#124;&nbsp;<a href="INDEXD61C.HTM?id=5" target="_self">Search</a>&nbsp;&#124;&nbsp;<a href="INDEX65E4.HTM?id=kontakt" target="_self">Contact</a>&nbsp;&#124;&nbsp;<a href="INDEXB7B8.HTM?id=204" target="_self">About INHN</a></div><a href="INDEX2999.HTM?id=202"><img class="headImg1" src="IMAGES/COMPANY_LOGO.GIF" alt="" title="Home" width="598" height="100" /></a></div>
		<div id="nav"><a id="navigation" name="navigation"></a><div id="nav_main" class="hlist"><ul><li id="current"><a href="INDEX2999.HTM?id=202" target="_self"><span>Home</span></a></li><li><a href="INDEX7EFD.HTM?id=479" target="_self"><span>Dictionary</span></a></li><li><a href="INDEX3E5C.HTM?id=374" target="_self"><span>Drugs</span></a></li><li><a href="INDEXDBB1.HTM?id=565" target="_self"><span>Photos</span></a></li><li><a href="INDEXD919.HTM?id=342" target="_self"><span>Profiles</span></a></li><li><a href="INDEXAF9F.HTM?id=355" target="_self"><span>Controversies</span></a></li><li><a href="INDEXD122.HTM?id=641" target="_self"><span>Discoveries</span></a></li><li><a href="INDEX1F24.HTM?id=384" target="_self"><span>Books</span></a></li><li><a href="INDEX3958.HTM?id=467" target="_self"><span>Biographies</span></a></li><li><a href="INDEX677F.HTM?id=642" target="_self"><span>Perspectives</span></a></li><li><a href="INDEX8C00.HTM?id=343" target="_self"><span>Archives</span></a></li><li><a href="INDEX06CB.HTM?id=368" target="_self"><span>Ebooks</span></a></li><li><a href="INDEXA1F1.HTM?id=1755" target="_self"><span>Collated</span></a></li><li><a href="INDEXDF25.HTM?id=4128" target="_self"><span>Multilingual Project</span></a></li><li><a href="INDEXABE4.HTM?id=3884" target="_self"><span>INHN Publisher</span></a></li></ul></div></div>
		<div id="main">
			<div id="teaser" class="clearfix"><div class="rootline">You are here: <a href="INDEX2999.HTM?id=202" target="_self">Home</a>&nbsp;/&nbsp;<a href="INDEX3F39.HTM?id=1016" target="_self">Central Office (Cordoba Unit)</a>&nbsp;/&nbsp;<a href="INDEXC279.HTM?id=1659" target="_self">EDUCATION</a>&nbsp;/&nbsp;<a href="INDEX768D.HTM?id=2359" target="_self">Thomas A. Ban Neuropsychopharmacology in Historical Perspective - Education in the Field in the Post-Neuropsychopharmacology Era</a>&nbsp;/&nbsp;Bulletin 34 : Starting Up (Volume One): 2. Psychiatry</div><div class="langMenu"><div class="tx-srlanguagemenu-pi1">
		
	</div>
	</div></div>
			<div id="col1">
				<div id="col1_content" class="clearfix">
					<ul id="submenu"><li id="title">Home</li><li><a href="INDEXB7B8.HTM?id=204" target="_self">About INHN</a><span class="hidden">.</span></li><li><a href="INDEXC104.HTM?id=854" target="_self">Towards education</a><span class="hidden">.</span></li><li><a href="INDEX3F39.HTM?id=1016" target="_self">Central Office (Cordoba Unit)</a><span class="hidden">.</span><ul><li><a href="INDEXEC89.HTM?id=1265" target="_self">Carlos Morra: Central Office</a></li><li><a href="INDEXF6AE.HTM?id=1234" target="_self">Administrative Unit by Leon S. Morra</a></li><li><a href="INDEXA81B.HTM?id=1233" target="_self">Carlos Morra: Chronological list of essential publications</a></li><li><a href="INDEXFC5C.HTM?id=3915" target="_self">Carlos Morra: Guide for Authors</a></li><li><a href="INDEX7A09.HTM?id=1123" target="_self">Thomas A. Ban: Recommended additions</a></li><li><a href="INDEX15CB.HTM?id=1587" target="_self">ADMINISTRATIVE UNIT</a><span class="hidden">.</span></li><li><a href="INDEXC279.HTM?id=1659" target="_self">EDUCATION</a><span class="hidden">.</span><ul><li><a href="INDEX768D.HTM?id=2359" target="_self">Thomas A. Ban Neuropsychopharmacology in Historical Perspective - Education in the Field in the Post-Neuropsychopharmacology Era</a><span class="hidden">.</span><ul><li><a href="INDEX114E.HTM?id=2360" target="_self">Bulletin 1: Educational Series 2. Jacques-Joseph Moreau de Tours.</a></li><li><a href="INDEX9E33.HTM?id=2367" target="_self">Bulletin 2 : Educational Series 2.Prologue</a></li><li><a href="INDEX1338.HTM?id=2375" target="_self">Bulletin 3 : Educational Series 2.  Vignette 1 Overview of the series: An Oral History of Neuropsychopharmacology</a></li><li><a href="INDEXF2B4.HTM?id=2385" target="_self">Bulletin 4 : Educational Series 2. Chapter 1: John Dalton’s atomic theory and drugs in psychiatry in the 19th century</a></li><li><a href="INDEXAEB2.HTM?id=2388" target="_self">Educational Series 2. Bulletin 5. Vignette 2: Sedatives in the second part of the 19th century</a></li><li><a href="INDEX8D36.HTM?id=2399" target="_self">Educational Series 2. Bulletin 6, Chapter 2: From William Cullen’s “neuroses” to Johann Christian Reil’s “psychiaterie”</a></li><li><a href="INDEX05B0.HTM?id=2404" target="_self">Educational Series 2. Bulletin 7, Vignette 3: Classifications of insanity in the late 18th and early 19th century</a></li><li><a href="INDEX525B.HTM?id=2414" target="_self">Educational Series 2. Bulletin 8, Chapter 3: Substances with an effect on consciousness</a></li><li><a href="INDEXA355.HTM?id=2422" target="_self">Educational Series 2. Bulletin 9 Vignette 4 :The isolation of morphine</a></li><li><a href="INDEX3BEE.HTM?id=2431" target="_self">Bulletin 10 : Reflexes of the brain</a></li><li><a href="INDEX8D24_2.HTM?id=2438" target="_self">Bulletin 11 : Sechenov’s re-evaluation of mental faculties and the brain</a></li><li><a href="INDEX796C.HTM?id=2451" target="_self">Bulletin 12 : Bayle’s discovery and the re-evaluation of the concept of dementia</a></li><li><a href="INDEX76A9_2.HTM?id=2458" target="_self">Bulletin 13 : Louis Sokoloff Autobiography – Regional mapping and imaging of the nervous system</a></li><li><a href="INDEXD4A9_2.HTM?id=2463" target="_self">Bulletin 14 : Joseph J. Schildkraut: Autobiography – The catecholamine hypothesis before and thereafter</a></li><li><a href="INDEXD5AC.HTM?id=2474" target="_self">Bulletin 15 : Alfred Pletscher Autobiography – On the Eve of the Birth of the Neurotransmitter Era in Biological Psychiatry</a></li><li><a href="INDEX6102.HTM?id=2483" target="_self">Bulletin 16 : Leo E. Hollister’s Interview of Julius Axelrod – The Uptake of Neurotransmitters and Psychoactive Drugs</a></li><li><a href="INDEXD4EC.HTM?id=2491" target="_self">Bulletin 17 : Thomas A. Ban’s Interview of Irwin J. Kopin – Metabolic disposition of catecholamines</a></li><li><a href="INDEXD604.HTM?id=2506" target="_self">Bulletin 18 : Thomas A. Ban’s Interview of Philip B. Bradley – Recording Electrical Activity from Cerebral Cortex and Subcortical Structures in Conscious Cats</a></li><li><a href="INDEXCD11.HTM?id=2521" target="_self">Bulletin 19 : From Conditioning and Psychiatry to Psychopharmacology*</a></li><li><a href="INDEX036F.HTM?id=2524" target="_self">Bulletin 20 : Conditioning and Psychiatry</a></li><li><a href="INDEXA67B.HTM?id=2533" target="_self">Bulletin 21 : Psychopharmacology</a></li><li><a href="INDEXA9EE_2.HTM?id=2543" target="_self">Bulletin 22 : Physiological patterns: A diagnostic test procedure based on the conditional reflex method</a></li><li><a href="INDEX8191.HTM?id=2551" target="_self">Bulletin 23 : Clinical pharmacology of psychotropic drugs</a></li><li><a href="INDEX0FE8.HTM?id=2562" target="_self">Bulletin 24 : Methodology and pitfalls in clinical testing of psychopharmacological drugs</a></li><li><a href="INDEX840B.HTM?id=2570" target="_self">Bulletin 25 : Toxicity and Adverse Reaction Studies with Neuroleptics and Antidepressants</a></li><li><a href="INDEX739E.HTM?id=2578" target="_self">Bulletin 26 : The effect of phenothiazines on the electrocardiogram</a></li><li><a href="INDEXF797.HTM?id=2586" target="_self">Bulletin 27 : Skin pigmentation, a rare side effect of chlorpromazine</a></li><li><a href="INDEX825E.HTM?id=2594" target="_self">Bulletin 28 : Ernst Feuchtersleben’s separation of psychosis from neurosis</a></li><li><a href="INDEXDC51.HTM?id=2603" target="_self">Bulletin 29 : Wilhelm Griesinger and Unitary Psychosis (Einheitpsychose)</a></li><li><a href="INDEX0C60.HTM?id=2612" target="_self">Bulletin 30 : Towards Neuropsychopharmacology in 1957</a></li><li><a href="INDEX76BD.HTM?id=2621" target="_self">Bulletin 31 : Fifty years CINP</a></li><li><a href="INDEX2103.HTM?id=2630" target="_self">Bulletin 32 : Fifty years ACNP</a></li><li><a href="INDEX6B55.HTM?id=2638" target="_self">Bulletin 33 : Starting Up (Volume One): 1. The Interviews</a></li><li><strong>Bulletin 34 : Starting Up (Volume One): 2. Psychiatry</strong></li><li><a href="INDEX22AE.HTM?id=2656" target="_self">Bulletin 35 : Starting Up (Volume One): 3. Drugs</a></li><li><a href="INDEXC051.HTM?id=2665" target="_self">Bulletin 36 : Starting Up (Volume One): 4. Pharmacology</a></li><li><a href="INDEX3552.HTM?id=2674" target="_self">Bulletin 37 : Starting Up (Volume One):  5. Interviewees</a></li><li><a href="INDEXBF4E.HTM?id=2683" target="_self">Bulletin 38 : Neurophysiology (Volume Two): 1. Early Development</a></li><li><a href="INDEXF887.HTM?id=2692" target="_self">Bulletin 39 : Neurophysiology (Volume Two): 2. Interviewees Contributions</a></li><li><a href="INDEX7741.HTM?id=2700" target="_self">Bulletin 40 : Neuropharmacology (Volume Three): 1. Neurotransmitters</a></li><li><a href="INDEXC58E.HTM?id=2708" target="_self">Bulletin 41 : Neuropharmacology (Volume Three): 2. Psychotropic drugs</a></li><li><a href="INDEX917B.HTM?id=2717" target="_self">Bulletin 42 : Neuropharmacology (Volume Three): 3a. Contributions of Interviewees</a></li><li><a href="INDEXBBC9.HTM?id=2726" target="_self">Bulletin 43 : Neuropharmacology (Volume Three): 3b. Contributions of Interviewees</a></li><li><a href="INDEX5AFC.HTM?id=2734" target="_self">Bulletin 44 : Psychopharmacology (Volume Four): 1. Clinical methodology</a></li><li><a href="INDEX5441.HTM?id=2751" target="_self">Bulletin 45 : Psychopharmacology (Volume Four): 2a. Contributions of Interviewees</a></li><li><a href="INDEXBB17.HTM?id=2760" target="_self">Bulletin 46 : Psychopharmacology (Volume Four): 2b. Contributions of Interviewees</a></li><li><a href="INDEX9F22.HTM?id=2761" target="_self">Bulletin 47 : Psychopharmacology (Volume Four): 2c. Contributions of Interviewees</a></li><li><a href="INDEXEFAA.HTM?id=2770" target="_self">Bulletin 48 : Neuropsychopharmacology (Volume Five): 1.Model Psychosis</a></li><li><a href="INDEX0571.HTM?id=2778" target="_self">Bulletin 49 : Neuropsychopharmacology (Volume Five): 2. Psychotoxic metabolites</a></li><li><a href="INDEX5740.HTM?id=2787" target="_self">Bulletin 50 : Neuropsychopharmacology (Volume Five): 3. Psychopharmacology of Schizophrenia; Psychopharmacology of Depression; Endocrine Measures</a></li><li><a href="INDEX47D5.HTM?id=2795" target="_self">Bulletin 51 : Neuropsychopharmacology (Volume Five): 4a. Contributions of Interviewees</a></li><li><a href="INDEXEE5A_2.HTM?id=2801" target="_self">Bulletin 52 : Neuropsychopharmacology (Volume Five): 4b. Contributions of Interviewees</a></li><li><a href="INDEX59FE.HTM?id=2810" target="_self">Bulletin 53 : Neuropsychopharmacology (Volume Five): 4c. Contributions of Interviewees</a></li><li><a href="INDEX0E71.HTM?id=2820" target="_self">Bulletin 54 : Addiction (Volume Six): 1. Addiction Psychiatry</a></li><li><a href="INDEXAE91.HTM?id=2829" target="_self">Bulletin 55 : Addiction (Volume Six): 2. Substances of abuse</a></li><li><a href="INDEX9B7D.HTM?id=2837" target="_self">Bulletin 56 : Addiction (Volume Six): 3. Conditioning and addiction</a></li><li><a href="INDEX0047_2.HTM?id=2846" target="_self">Bulletin 57 : Addiction (Volume Six): 4a. Contributions of interviewees</a></li><li><a href="INDEX44BA.HTM?id=2854" target="_self">Bulletin 58 : Addiction (Volume Six): 4b. Contributions of interviewees.</a></li><li><a href="INDEX0F23.HTM?id=2863" target="_self">Bulletin 59 : Special Areas (Volume Seven): 1. Child Psychiatry</a></li><li><a href="INDEXAA86.HTM?id=2871" target="_self">Bulletin 60 : Special Areas (Volume Seven): 2. Geriatric Psychiatry</a></li><li><a href="INDEX9ECC.HTM?id=2883" target="_self">Bulletin 61 : Special Areas (Volume Seven): 3. Psychiatric diagnosis</a></li><li><a href="INDEX1EC3.HTM?id=2892" target="_self">Bulletin 62 : Special Areas (Volume Seven): 4. Pharmacokinetics</a></li><li><a href="INDEXBAEC.HTM?id=2902" target="_self">Bulletin 63 : Special Areas (Volume Seven): 5a. Contributions of Interviewees.</a></li><li><a href="INDEX38B7.HTM?id=2921" target="_self">Bulletin 64 : Special Areas (Volume Seven): 5b. Contributions of Interviewees</a></li><li><a href="INDEX54DB.HTM?id=2938" target="_self">Bulletin 65 : Special Areas (Volume Seven): 5c. Contributions of Interviewees</a></li><li><a href="INDEX5194.HTM?id=2952" target="_self">Bulletin 66 : Diverse Topics (Volume Eight): 1. Regulation, Ethics, Marketing and Education, Conflict of Interest</a></li><li><a href="INDEXF272.HTM?id=2960" target="_self">Bulletin 67 : Diverse Topics (Volume Eight): 2a. Interviewees Contributions</a></li><li><a href="INDEXCAF4.HTM?id=2969" target="_self">Bulletin 68 : Diverse Topics (Volume Eight): 2b. Interviewees Contributions</a></li><li><a href="INDEX8272.HTM?id=2979" target="_self">Bulletin 69 : Update (Volume Nine): 1. Pharmacogenetics and Genetics and Neuropsychopharmacology</a></li><li><a href="INDEXBD8C.HTM?id=2988" target="_self">Bulletin 70 : Update (Volume Nine): 2. Psychopathology and Nosology</a></li><li><a href="INDEX2A75.HTM?id=3004" target="_self">Bulletin 71 : Update (Volume Nine): 3a. Interviewee’s Contributions</a></li><li><a href="INDEX48C2.HTM?id=3021" target="_self">Bulletin 72 : Update (Volume 9) 3b. Interviewees contributions</a></li><li><a href="INDEX616E.HTM?id=3030" target="_self">Bulletin 73 : Volume 10. Postscript</a></li><li><a href="INDEX1D4A.HTM?id=3036" target="_self">Bulletin 74 : An Overview of Developments in Psychopharmacology and Neuropsychopharmacology</a></li><li><a href="INDEX2F0A.HTM?id=3048" target="_self">Bulletin 75 : The confounding of education with marketing</a></li><li><a href="INDEX1E85.HTM?id=3055" target="_self">Bulletin 76 : Towards a genetic era in neuropsychopharmacology</a></li><li><a href="INDEX5072.HTM?id=3062" target="_self">Bulletin 77 : The CODE System</a></li><li><a href="INDEXBB3A.HTM?id=3071" target="_self">Bulletin 78 : Nosologic Homotyping</a></li><li><a href="INDEX5262.HTM?id=3085" target="_self">Collated Bulletin 1: RDoC in Historical Perspective.</a></li><li><a href="INDEX8197.HTM?id=3094" target="_self">Collated Bulletin 2 : Neuropsychopharmacology and the Forgotten Language of Psychiatry</a></li><li><a href="INDEXCB60.HTM?id=3103" target="_self">Collated Bulletin 3 : In Historical Perspective: Peralta, Cuesta and their associate’s findings on the highest familiality of Leonhard’s Classification in Polynosologic Study</a></li><li><a href="INDEX55BE.HTM?id=3111" target="_self">Collated Bulletin 4: Thomas A. Ban: The Birth of a Medical Discipline: Psychiatry</a></li><li><a href="INDEX1328.HTM?id=3124" target="_self">Collated Bulletin 5: Thomas A. Ban: Conflict of Interest in Neuropsychopharmacology. Marketing vs. Education.</a></li><li><a href="INDEX9A64.HTM?id=3130" target="_self">Collated Bulletin 6: Edward Shorter: The QT interval and the Mellaril story</a></li><li><a href="INDEXC9E3.HTM?id=3143" target="_self">Collated Bulletin 7 : Thomas A. Ban: The Wernicke – Kleist – Leonhard Tradition with Special Reference to Mania, Melancholia and Manic – Depressive Psychosis</a><span class="hidden">.</span></li><li><a href="INDEX1124.HTM?id=3152" target="_self">Collated Bulletin 8 : Thomas A. Ban: The Birth of Drug Industry and Drugs with An Effect On Behavior</a></li><li><a href="INDEX1A41.HTM?id=3164" target="_self">Collated Bulletin 9 : Thomas A. Ban: From Melancholia to Depression</a></li><li><a href="INDEX4A53.HTM?id=3170" target="_self">Collated Bulletin 10 : Thomas A. Ban: The Year 1845</a></li><li><a href="INDEX4878.HTM?id=3182" target="_self">Collated Bulletin 11 : Joseph Knoll: The discovery of monoamine oxidase (MAO) enzymes</a><span class="hidden">.</span></li><li><a href="INDEX13FE.HTM?id=3200" target="_self">Collated Bulletin 12 : Samuel Gershon: Events and Memories</a></li><li><a href="INDEXBAD0.HTM?id=3287" target="_self">Collated Bulletin 13 : Paul Devenyi: Addictions are not treatable diseases and Pharmacotherapy of addiction not a success story.</a></li><li><a href="INDEX80F0.HTM?id=3297" target="_self">Collated Bulletin 14 : Janos Radó: The use of modern antidiuretic agents in the treatment of permanent lithium-induced nephrogenic diabetes insipidus</a></li><li><a href="INDEX7FB2.HTM?id=3305" target="_self">Collated Bulletin 15 : Per Bech:  Clinical Psychometrics</a></li><li><a href="INDEX2912.HTM?id=3312" target="_self">Collated Bulletin 16 : Martin M. Katz: Onset of clinical effects of antidepressants</a></li><li><a href="INDEX412B.HTM?id=3321" target="_self">Collated Bulletin 17 : Martin M. Katz: Depression and Drugs, a monograph  and Multivantaged vs Conventional Assessment, an essay</a></li><li><a href="INDEXB116.HTM?id=3330" target="_self">Collated Bulletin 18 : Per Bech:  Measurement-based care in mental disorders (New York: Springer; 2016) Foreword and Review</a></li><li><a href="INDEX8100.HTM?id=3338" target="_self">Collated Bulletin 19 : Donald F. Klein and John Davis: Diagnosis and Drug Treatment of Mental Disorders and Thomas A. Ban: Psychopharmacology in 1969</a></li><li><a href="INDEX7B0A.HTM?id=3345" target="_self">Collated Bulletin 20 : Thomas A. Ban: Schizophrenia in the Early 1970s</a></li><li><a href="INDEXAF2B.HTM?id=3355" target="_self">Collated Bulletin 21 : Thomas A. Ban, Marcelo Cetkovich-Bakmas, Ernst Franzek and Hector Warnes: Carl Wernicke’s “elementary symptoms” and “sejunction hypothesis”</a></li><li><a href="INDEXE783.HTM?id=3374" target="_self">Collated Bulletin 22 : Martin M. Katz: Clinical Trials of Antidepressants: How Changing the Model Can Uncover New, More Effective Molecules</a></li><li><a href="INDEX4AF0.HTM?id=3393" target="_self">Collated Bulletin 23 : Joseph Knoll: From the Theory of Active Reflexes to a Neurochemical Concept of Innate and Acquired Drive</a></li><li><a href="INDEXC922.HTM?id=3401" target="_self">Collated Bulletin 24 : Ildiko Miklya: The  History of Selegiline (-) Deprenyl the First Selective Inhibitor of B-Type Monoamine Oxidase and the First Synthetic Catecholaminergic Enhancer Substance</a></li><li><a href="INDEX5549.HTM?id=3411" target="_self">Collated Bulletin 25 : Joseph Knoll: The Discovery of the Enhancer Regulation in the Mammalian Brain and the Development of the Synthetic Enhancer Substances</a></li><li><a href="INDEXBEF3.HTM?id=3421" target="_self">Collated Bulletin 26 : Profiles of clinicians and researchers who were instrumental for the birth and/or contributed to the development of neuropsychopharmacology: Julius Axelrod, Frank Ayd, Frank Berger, Hans Berger and Hermann Blaschko</a></li><li><a href="INDEXDEB4.HTM?id=3428" target="_self">Collated Bulletin 27 : Profiles of clinicians and researchers who were instrumental for the birth and/or contributed to the development of neuropsychopharmacology. Charles Bradley, Philip B. Bradley, Bernard B. Brodie, John Cade and John Delay</a></li><li><a href="INDEX65AD.HTM?id=3436" target="_self">Collated Bulletin 28 : Profiles of clinicians and researchers who were instrumental for the birth and/or contributed to the development of neuropsychopharmacology. Edmundo Fischer, W. Horsley Gantt, Turan M. Itil, Hitoshi Itoh and Paul Kielholz</a></li><li><a href="INDEX9D53.HTM?id=3446" target="_self">Collated Bulletin 29 : Profiles of clinicians and researchers who were instrumental for the birth and/or contributed to the development of neuropsychopharmacology. Nathan S. Kline, Roland Kuhn, Heinz E. Lehmann, Laszlo Meduna and Dionisio Nieto Gomez</a></li><li><a href="INDEX05ED.HTM?id=3454" target="_self">Collated Bulletin 30 : Profiles of clinicians and researchers who were instrumental for the birth and/or contributed to the development of neuropsychopharmacology. Alfred Pletscher, Juri Saarma, Sydney Spector, Leo Sternbach, Edward Trautner and Joseph Wo</a></li><li><a href="INDEX51CB.HTM?id=3464" target="_self">Collated Bulletin 31 : Thomas A. Ban: Lithium. 1. Discovery of its therapeutic effect in psychiatry. Johan Schioldann, William T. Hammond and Carl Lange</a></li><li><a href="INDEX7AE6.HTM?id=3471" target="_self">Collated Bulletin 32 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective. 2. Introduction into treatment in psychiatry. Samuel Gershon: Profiles of John Cade and Edward Trautner</a></li><li><a href="INDEX9492.HTM?id=3479" target="_self">Collated Bulletin 33 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective. 3. Early Years. Samuel Gershon: First-Hand Accounts</a></li><li><a href="INDEX5A82.HTM?id=3489" target="_self">Collated Bulletin 34 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective</a></li><li><a href="INDEXBC82.HTM?id=3497" target="_self">Collated Bulletin 35 : Thomas A. Ban: Lithium. 4. Controversy. Barry Blackwell vs Paul Grof and Jules Angst</a></li><li><a href="INDEXE7C3.HTM?id=3506" target="_self">Collated Bulletin 36 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective 5. Turning point. Paul Grof and Johan Schioldann</a></li><li><a href="INDEXF857.HTM?id=3514" target="_self">Collated Bulletin 37 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective 6. Action. Janusz Rybakowski</a></li><li><a href="INDEX6E77.HTM?id=3523" target="_self">Collated Bulletin 38 : Thomas A. Ban: 7.  Diagnosis</a></li><li><a href="INDEX680B.HTM?id=3532" target="_self">Collated Bulletin 39 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective Dedication and Preface</a></li><li><a href="INDEX516F.HTM?id=3541" target="_self">Collated Bulletin 40 : Thomas A. Ban: Lithium in Psychiatry in Historical Perspective.</a></li><li><a href="INDEX1901.HTM?id=3550" target="_self">Collated Bulletin 41 : Peter R. Martin. Volume 1. Recollections of the History of Neuropsychopharmacology Through Interviews Conducted by Thomas A. Ban</a></li><li><a href="INDEXCA36.HTM?id=3558" target="_self">Collated Bulletin 42 : Peter R. Martin. Volume 2. Recollections of the History of Neuropsychopharmacology Through Interviews Conducted by Leo E. Hollister</a></li><li><a href="INDEXE728.HTM?id=3566" target="_self">Collated Bulletin 43 : Peter R. Martin. Volume 2. Recollections of the History of Neuropsychopharmacology Through Interviews Conducted by William E. Bunney, Jr.</a></li><li><a href="INDEX0343.HTM?id=3583" target="_self">Lehmann Collection 1 : Charles E. Cahn’s interview of Heinz E. Lehmann</a><span class="hidden">.</span></li><li><a href="INDEXAF7B.HTM?id=3591" target="_self">Lehmann Collection 2 : William E. Bunney’s interview of Heinz E. Lehmann</a></li><li><a href="INDEXC461.HTM?id=3599" target="_self">Lehmann Collection 3 : Heinz Edgar Lehmann by Barry Blackwell</a></li><li><a href="INDEXC5D4.HTM?id=3607" target="_self">Lehmann Collection 4 : Heinz Lehmann and Douglas Hospital by Charles C. Cahn</a></li><li><a href="INDEXEC5F.HTM?id=3616" target="_self">Lehmann Collection 5 : Heinz Edgar Lehmann’s research profile by Antonio E. Nardi.</a></li><li><a href="INDEXDB89.HTM?id=3624" target="_self">Lehmann Collection 6 : Heinz E. Lehmann by Edward Shorter.</a></li><li><a href="INDEXB434.HTM?id=3633" target="_self">Lehmann Collection 7 : Per Bech’s comment on Heinz E. Lehmann*</a></li><li><a href="INDEX1767.HTM?id=3641" target="_self">Lehmann Collection 8 : Paul Grof’s comment on Heinz E. Lehmann. A few personal recollections</a></li><li><a href="INDEX7BD1.HTM?id=3650" target="_self">Lehmann Collection 9 : Irwin J. Kopin’s comment on Heinz E. Lehmann.</a></li><li><a href="INDEXAE03.HTM?id=3661" target="_self">Lehmann Collection 10 : Mary and Philip Seeman's comment</a></li><li><a href="INDEXDDD3.HTM?id=3680" target="_self">Lehmann Collection 11 : A Tribute to Heinz Edgar Lehmann by Hector Warnes.</a></li><li><a href="INDEX42F1.HTM?id=3689" target="_self">Lehmann Collection 12 : Heinz Edgar Lehmann:  Publication</a></li><li><a href="INDEX8FD0.HTM?id=3698" target="_self">Lehmann Collection 13 :  Thomas A. Ban: My Personal Notes on Heinz Lehmann</a></li><li><a href="INDEXC658.HTM?id=3707" target="_self">Lehmann Collection 14 : Thomas A. Ban: Heinz E. Lehmann and Psychopharmacology</a></li><li><a href="INDEXB918.HTM?id=3717" target="_self">Lehmann Collection 15 : Thomas A. Ban: Towards a clinical methodology for neuropsychological research</a></li><li><a href="INDEXF57D.HTM?id=3726" target="_self">Lehmann Collection 16 : Heinz Edgar Lehmann</a></li><li><a href="INDEX1FC5.HTM?id=3734" target="_self">Lehmann Collection 17 : Heinz E. Lehmann: What is wrong with getting old?</a></li><li><a href="INDEX1A9C.HTM?id=3743" target="_self">Lehmann Collection 18 : Heinz E. Lehmann: Dreaming about Mental Health</a></li><li><a href="INDEXDC72.HTM?id=3753" target="_self">Lehmann Collection 19: Heinz E. Lehmann: Alcoholism, aggression and androgen function. Discussion of paper by Jack Mendelson</a></li><li><a href="INDEX7FE1.HTM?id=3761" target="_self">Lehmann Collection 20: Heinz E. Lehmann: Perspectives in Psychosurgery</a></li><li><a href="INDEX6E26.HTM?id=3770" target="_self">Lehmann Collection 21 : Heinz E. Lehmann: Discussion of the paper by Prof. P. Pichot:  The Treatment of Depression</a></li><li><a href="INDEX2F04.HTM?id=3778" target="_self">Lehmann Collection 22 : Heinz E. Lehmann: Harlem Valley Revisited</a></li><li><a href="INDEX8D36_2.HTM?id=3788" target="_self">Lehmann Collection 23 : Heinz E. Lehmann: Chlorpromazine: The Story of Phenothiazine Derivatives, Their Clinical Indications, the Incidence and Management of Untoward Effects and a Proposed Rational for Its Action</a></li><li><a href="INDEXC42B.HTM?id=3796" target="_self">Lehmann Collection 24 : Heinz E. Lehmann: The Anatomy of Research Funding</a></li><li><a href="INDEX7DC1.HTM?id=3804" target="_self">Lehmann Collection 25 : Program of Academic morning in honor of Dr. Heinz Lehmann</a></li><li><a href="INDEX212A.HTM?id=3814" target="_self">Lehmann Collection 26 : Heinz E. Lehmann: Types and Characteristics of Objective Measures of Psychopathology</a></li><li><a href="INDEX40D0.HTM?id=3877" target="_self">Classification of Functional Psychoses 1 : Preface and Recommended Reading</a></li><li><a href="INDEXF49C.HTM?id=3888" target="_self">Classification of Functional Psychoses 2 : Introduction</a></li><li><a href="INDEX12CF.HTM?id=3896" target="_self">Classification of Functional Psychoses 3 : ICD-9 and DSM-III</a></li><li><a href="INDEX93EE.HTM?id=3906" target="_self">Classification of Functional Psychoses 4: Classification of Mental Disorders and Psychopharmacology – Diagnostic Criteria for Research</a></li><li><a href="INDEX0CDC.HTM?id=3914" target="_self">Classification of Functional Psychoses 5: The KDK Budapest</a></li><li><a href="INDEX6A56.HTM?id=3923" target="_self">Classification of Functional Psychoses 6: One- and Two-Dimensional Diagnoses</a></li><li><a href="INDEX44FB.HTM?id=3933" target="_self">Classification of Functional Psychoses 7: Delusional Development and Delusional Psychoses</a></li><li><a href="INDEXA244.HTM?id=3942" target="_self">Classification of Functional Psychoses 8: Bayle’s Unitary Concept of Psychosis and Endogenous Psychoses</a></li><li><a href="INDEX76A8.HTM?id=3952" target="_self">Classification of Functional Psychoses 9: Affective Psychosis</a></li><li><a href="INDEXF554.HTM?id=3960" target="_self">Classification of Functional Psychoses 10: Empirical and Pragmatic Classifications of Depression</a></li><li><a href="INDEXB28B.HTM?id=3969" target="_self">Classification of Functional Psychoses 11: Schizophrenic Psychoses</a></li><li><a href="INDEXEE78.HTM?id=3977" target="_self">Classification of Functional Psychoses 12: Cycloid Psychoses</a></li><li><a href="INDEX79BA.HTM?id=3985" target="_self">Classification of Functional Psychoses 13: Conclusions</a></li><li><a href="INDEXFDAB.HTM?id=3994" target="_self">Classification of Functional Psychoses 14: References</a></li><li><a href="INDEXF3F8.HTM?id=4011" target="_self">Delcir da Costa’s comment on collating document</a></li><li><a href="INDEXFAD4.HTM?id=4030" target="_self">Dementia Differential Diagnosis 1991 : Contents</a></li><li><a href="INDEX05BB.HTM?id=4042" target="_self">Dementia Differential Diagnosis 1991 : Conceptual Development</a></li><li><a href="INDEXA331.HTM?id=4051" target="_self">Dementia Differential Diagnosis 1991 : Dementing Illnesses</a></li><li><a href="INDEXDEF5.HTM?id=4059" target="_self">Dementia Differential Diagnosis 1991 : Modified Concept</a></li><li><a href="INDEX4686.HTM?id=4068" target="_self">Dementia Differential Diagnosis 1991 : Diagnosing of Dementing Illness</a></li><li><a href="INDEXED54.HTM?id=4077" target="_self">Dementia Differential Diagnosis 1991 : References</a></li><li><a href="INDEX0D43.HTM?id=4132" target="_self">Methodology pitfalls of clinical testing of psychopharmaceutical</a></li><li><a href="INDEX9601.HTM?id=4140" target="_self">Mental health (Psychiatry) and pharmaceuticals in a historical perspective</a></li><li><a href="INDEX114D.HTM?id=4150" target="_self">Nosology in the teaching of psychiatry. Introduction</a></li><li><a href="INDEX4294.HTM?id=4158" target="_self">Towards a clinical methodology for neuropsychopharmacological research</a></li><li><a href="INDEXD825.HTM?id=4176" target="_self">Selective Drugs Versus Heterogeneous Diagnoses. Towards a New Methodology in Psychopharmacologic Research</a></li></ul></li><li><a href="INDEXC4F2.HTM?id=2324" target="_self">Per Bech: Members of the International Committee for the Prevention and Treatment of Depression in the mid-1980s</a></li><li><a href="INDEXC2D5.HTM?id=2299" target="_self">Per Bech and Wolfgang Rutz: The Story of the International Committee for the Prevention and Treatment of Depression</a></li><li><a href="INDEX9256.HTM?id=2371" target="_self">Peter R. Martin: Historical Dictionary of Addiction</a><span class="hidden">.</span></li><li><a href="INDEX527D.HTM?id=2648" target="_self">Amara McLaughlin-Harris: The Legal History of Psychoactive Drugs</a><span class="hidden">.</span></li><li><a href="INDEXFB23.HTM?id=2184" target="_self">Carlos Morra: An Educational Model in Psychiatry</a><span class="hidden">.</span></li><li><a href="INDEX9A07.HTM?id=2428" target="_self">Carlos Morra and Ernst Franzek: Psychopathological Symptoms</a><span class="hidden">.</span></li><li><a href="INDEX0793.HTM?id=3533" target="_self">Carlos Morra and Mateo Kreiker: Psychopathology</a><span class="hidden">.</span></li></ul></li></ul></li><li><a href="INDEX4710.HTM?id=3072" target="_self">INHN Publisher</a><span class="hidden">.</span></li><li><a href="INDEX7227.HTM?id=1114" target="_self">Programs</a><span class="hidden">.</span></li><li><a href="INDEXEAE0.HTM?id=1266" target="_self">Courses</a><span class="hidden">.</span></li><li><a href="INDEX86F6.HTM?id=1296" target="_self">Interviews</a><span class="hidden">.</span></li><li><a href="INDEXEF79.HTM?id=410" target="_self">Copyright Policy</a></li><li><a href="INDEX756E.HTM?id=437" target="_self">How to cite INHN</a></li><li><a href="INDEXCF6F.HTM?id=3373" target="_self">Website Table of Contents</a></li><li><a href="INDEXD254.HTM?id=2343" target="_self">Last Uploads</a></li></ul>
					
					<div class="textBelowMenu"><!--TYPO3SEARCH_begin--><!--TYPO3SEARCH_end--></div>
				</div>
			</div>
			<div id="col2">
				<div id="col2_content" class="clearfix"><!--TYPO3SEARCH_begin--><!--TYPO3SEARCH_end--></div>
			</div>
			<div id="col3">
			  <a id="content" name="content"></a>
				<div id="col3_content" class="clearfix">
					<div class="floatbox"><!--TYPO3SEARCH_begin--><!--DMAILER_SECTION_BOUNDARY_--><div id="c4482" class="csc-default"><h1><span style="font-weight: normal;">Thomas A. Ban<br />Neuropsychopharmacology in Historical Perspective<br />Education in the Field in the Post-Neuropsychopharmacology Era</span><br /><b>Background to An Oral History of the First Fifty Years<br /> </b><b>Starting Up (Volume One): 2. Psychiatry<br /></b><b>(Bulletin 34)</b></h1>
<p>&nbsp;</p>
<p>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Naturally occurring substances have been used to heal the mind and induce ecstasy throughout history. Yet the story that leads to the development of neuropsychopharmacology begins only in the early 19<sup>th</sup> century with the emergence of organic chemistry, pharmacology. and the pharmaceutical industry (Ban 2006; Healy 1997).The rapid growth of drug companies during the second half of the 19<sup>th</sup> century was instrumental to the introduction of several centrally acting drugs. By the end of the 1890s morphine,a substance isolated from opiumalong with apomorphine and hyoscine (scopolamine), was extensively used in the control of excitement and agitation; chloral hydrate and paraldehyde for calming and inducing sleep; and potassium bromidefor relieving restlessness, anxiety and tension (Cervello 1882; Joynt 1974; Liebig 1832; Liebreich 1869; Serturner 1806; Shorter 2005; Wood 1855). The use of these drugs provided day-and night time sedation in the asylums and reduced the need for physical restraint (Ban 2006). It was during this period – between 1850 and 1900 – that academic psychiatry was born with more than 20 academic departments established in German-speaking universities alone (Shorter 1997, 2005).</p>
<p>By the end of the 19<sup>th</sup> century, pharmacological control of behavior made it possible to study the symptoms and signs of psychiatric patients during the entire course of their illness (Ban 2006).The information collected opened the path for the further development of psychopathology, the discipline that deals with the symptoms and signs of psychiatric disease,and psychiatric nosology, the discipline that deals with the methodology of synthesizing and classifying diseases (Boissier de Sauvages 1768; Jaspers 1910, 1913; Kahlbaum 1863).During the first half of the 20<sup>th, </sup>century psychopathology provided a common language for the description of the mental state of patients, and nosology the necessary orientation points to classify them into groups with some predictability of behavior and response to treatment. In the new classification, the psychoses – which originally included all mental pathologies – were split into “organic”and “endogenous”; the “endogenous psychoses” were divided into manic-depressive insanity (illness) and dementia praecox (schizophrenia); the “exogenous (toxic) psychoses” were distinguished from the “reactive (psychogenic) psychoses”; and the “psychoses” (manifestations of disease) were separated from the “personality disorders” (manifestations of anomalous development) (Bayle 1826; Bonhoeffer 1909; Feuchtersleben 1845; Jaspers 1910; Kraepelin 1896, 1899; Mobius 1893; Schneider 1950; Wimmer 1916).&nbsp; </p>
<p>Simultaneously with the development of modern psychiatry, the armamentarium of drugs used in psychiatric disorders had grown. In 1903 the barbiturates, a group of sedative drugs appeared; they found their place in clinical practice in a variety of disorders, including insomnia, epilepsy and inhibited catatonia (Fischer and Mering 1903; Lehmann and Ban 1970; Thorner 1935). They were also used in general anesthesia and in the facilitation of psychotherapy (Lehmann and Ban1970). In 1936, after the recognition of their central nervous system stimulating effect (initially described in 1927), the amphetamines entered the psychiatric scene; Benzedrine (amphetamine sulfate) was shown to have therapeutic effect in narcolepsyand in calming hyper-excitable and hyperactive children (Alles 1927; Bradley 1937; Prinzmetal and Blumberg 1935).In the 1940s, with the introduction of nicotinic acidand penicillin, cerebral pellagraand cerebral syphilis were wiped out in psychiatry; and with the introduction of thiamine and diphenylhydantoin the psychiatric population with amnestic syndrome and epilepsy was drastically decreased in psychiatric hospitals (De Wardener and Lennox 1947; Elvehjem et al.&nbsp; 1937; Fleming 1929; Fouts et al. 1937; Jansen and Donath 1926; Putnam 1970; Stokes et al. 1944; Wernicke 1881).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p>
<p>The use of drugs in the study of mental pathology – advocated in the mid-19<sup>th</sup> century by Moreau de Tours – was re-vitalized with the introduction of phenomenological psychopathology, the branch of psychopathology that deals with the subjective experiences of psychic life (Jaspers 1913; Moreau de Tours 1845).Initially, phenomenological studies with mescaline, the active ingredient of peyote (a cactus plant),were in vogue (Beringer 1927; Knauer and Maloney 1913; Lehmann 1993; Lewin 1931.) Interest shifted to lysergic acid diethylamide (LSD), an ergot alkaloid, after its accidental discovery in 1943 by Hofmannwhile working with synthetic ergot alkaloids in order to develop a nikethamide-like analeptic in the laboratories of Sandoz, a Swiss pharmaceutical company at the time (Hofmann 1970; Stoll and Hofmann 1943). LSD was more than 1,000 times more potent than mescaline; it was active in 0.5 to 1.0 microgram per kilogram (Brown 1972).The possibility that a chemical in such minute amounts could induce hallucinations had fueled the contemporary hypothesis that undetectable traces of psychoactive substances produced by the body might be responsible for the pathogenesis of some mental illness.</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The idea that autointoxication plays a role in the pathogenesis of some psychoses entered psychiatry in the 1930s with Rolv Gjessing’s finding of nitrogen retention in certain phases of periodic catatonia (Gjessing 1938). His postulation that the alteration of metabolism by the production of mescaline-like substances in the body is responsible for periodic catatonia profoundly affected psychiatric thinking in the 1940s and ’50s. John Cade,stimulated by the work of Gjessing and Hofmann,hypothesized that mania, as thyrotoxicosis, was a state of intoxication by a product of the body in excess, and melancholia, as myxedema, was a state of deficiency of the same substance (Cade 1948, 1970; Gjessing 1938; Stoll and Hofmann 1943). The hypothesis was wrong, but it led to the serendipitous discovery of the therapeutic effect of lithium in mania in the late 1940s (Cade 1948).</p>
<p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Autointoxication, combined with Walter Cannon’s findings about the role of the adrenals in the adaptation to stress, is at the core of Osmond and Smythies (1952) postulation that schizophrenia is the result of stress-induced anxiety and a failure in the metabolism of norepinephrine. Harley-Mason (1952) suggested that a trans-methylation product of norepinephrine, DMPEA (3, 4- dimethoxyphenylalanine) – a toxic substance that could induce experimental catatonia– was responsible for the pathogenesis of schizophrenia; Hoffer, Osmond and Smythiesproposed that adrenochrome, an oxidation product of epinephrine,was the culprit (Ban and Lehmann 1970; Green and Richter1937; Harley-Mason 1952; Hoffer, Osmond and Smythies 1954; Noteboom 1934; Osmond and Smythies 1952). Both hypotheses were wrong. Yet they stimulated research in the biochemistry of mental illness in a period (1950s) when psychodynamic schools dominated psychiatry in North America and schizophrenia (“schizophrenic reactions”) was perceived as the outcome of poor mothering manifesting as narcissistic withdrawal with regression to early autoerotic stages of ego development (Noyes and Kolb 1958).</p>
<p>It was against this background that within a period of five years five effective pharmacological treatments appeared on the psychiatric scene.</p>
<p>&nbsp;</p>
<p><b>References:</b></p>
<p>Alles GA. The comparative physiological action of phenylethanolamine. J Pharmacol 1927; 32: 121–33.</p>
<p>Ban TA. Academic psychiatry and the pharmaceutical industry. Prog Neuro-Psychopharmacol Biol Psychiatry 2006; 30: 429–41.</p>
<p>Bayle ALJ. Traité des Maladies du Cerveau et de ses Membranes. Paris: Gabon; 1826.</p>
<p>Beringer K. Mescaline Intoxication. Berlin: Springer; 1927.</p>
<p>Boissier de Sauvages F. Nosologia Methodica. Amsterdam: Frat de Tournes; 1768.</p>
<p>Bonhoeffer K. Zur Frage der exogenen Psychosen. Neur Zbl 1909; 32: 499–505.</p>
<p>Bradley CB. The behavior of children receiving Benzedrine. Am J Psychiatry 1937; 94; 577-80.</p>
<p>Brown FC. Hallucinogenic Drugs. Springfield: Charles C. Thomas; 1972.</p>
<p>Cade JF. The story of lithium. In: Ayd FJ, Jr, Blackwell B, editors. Discoveries in Biological Psychiatry. Philadelphia: Lippincott; 1970, p. 218–29.</p>
<p>Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust 1948; 2: 349 – 52.</p>
<p>Cervello V. Über die Physiologische Wirkung des Paraldehyds und Beiträge zu den Studien über das Chloralhydrate. Arch Exp Path Pharmacol 1882; 16: 265–90.</p>
<p>De Wardener HE, Lennox B. Cerebral beri-beri (Wernicke’s encephalopathy): review of 52 cases in Singapore prisoner-of-war hospital. Lancet 1947; 1: 11–7.</p>
<p>Elvehjem CA, Madden RJ, Strong FM, Wooley DW. The isolation and the identification of the anti-black tongue factor. J Biol Chem 1937; 123: 137–49.</p>
<p>Feuchtersleben E. Lehrbuch der Ärztlichen Seelenkunde. Vienna: Carl Gerold; 1845.</p>
<p>Fischer E, Mering von J. Über eine neue Klasse von Schlafmittels. Ther Ggw 1903; 44: 97–101.</p>
<p>Fleming A. On the antibacterial action of cultures of penicillium with special reference to their use in the isolation of B influenzae. Br J Exp Pathol 1929; 10: 226–36.</p>
<p>Fouts PJ, Helmer OM, Lepkovsky YS, Jukes TH. Treatment of human pellagra with nicotinic acid. Proc Soc Exp Biol Med 1937; 37: 405–7.</p>
<p>Gjessing R. Disturbances of somatic functions in catatonia with periodic course, and their compensation. J Ment Sci 1938; 84: 608–-21.</p>
<p>Green D, Richter D. Adrenalin and adrenochrome. Biochem J 1937; 31: 596–616.</p>
<p>Harley-Mason J (1952). In: Osmond H, Smythies J. Schizophrenia: a new approach. J Ment Sci 1952; 98: 309–15.</p>
<p>Healy D. The Antidepressant Era. Cambridge: Harvard University Press; 1997. p.17–21.</p>
<p>Hoffer A, Osmond H, Smythies J. Schizophrenia: a new approach II. J Ment Sci 1954; 100: 39–45.</p>
<p>Hofmann A. The discovery of LSD and subsequent investigations with naturally occurring hallucinogens. In: Ayd FJ, Jr, Blackwell B, editors. Discoveries in Biological Psychiatry. Philadelphia: Lippincott; 1970. p. 91–106.</p>
<p>Jansen BCP, Donath WF. On the isolation of antiberiberi vitamin. Proc K Ned Akad Wet 1926; 29: 1390–400.</p>
<p>Jaspers K. Eifersuchtswahn: Entwicklung einer Persönlichkeit oder Prozess. Z Ges Neurol Psychiatr 1910; 1: 567–637.</p>
<p>Jaspers K. Allgemeine Psychopathologie. Berlin: Springer; 1913.</p>
<p>Joynt RJ. The use of bromides in epilepsy. Am J Diseases of Children 1974; 128: 362– 3.</p>
<p>Kahlbaum K. Die Gruppierung der psychischen Krankheiten und die Enteilung der Seelenstoerungen. Danzig: AW Kaufman; 1863.</p>
<p>Knauer A, Maloney WM. Psychic action of mescaline.&nbsp; J Nerv Ment Dis 1913; 40: 425–40.</p>
<p>Kraepelin E. Psychiatrie. Ein Lehrbuch für Studierende und Ärzte. 5 Auflage. Leipzig: Barth; 1896.</p>
<p>Kraepelin E. Psychiatrie. Ein Lehrbuch der Studierende und Ärzte. 6 Auflage. Leipzig: Barth; 1899.</p>
<p>Lehmann HE. Before they called it psychiatry. Neuropsychopharmacology 1993; 8: 291–303.</p>
<p>Lehmann HE, Ban TA. Pharmacotherapy of Tension and Anxiety. Springfield: Charles C. Thomas; 1970. p.14–5.</p>
<p>Lewin L. Phantastica: Narcotic and Stimulating Drugs. Their Use and Abuse. London: Routledge; 1931.</p>
<p>Liebig J. Über die Verbindungen welche durch die Einwirkung des Chlors auf Alcohol, Aether,&nbsp;</p>
<p>Liebreich MEP. Das Chloralhydrate, ein neues Hypnoticum und Anaestheticum, und dessen Anwendung in die Medizin. Eine Arzneimeittel-Untersuchung. Berlin: Müller; 1869.</p>
<p>Möbius JP. Abriss der Lehre von den Nervenkrankheiten. Leipzig: Abel; 1893.</p>
<p>Moreau de Tours J. Du Hachich et de L’Aliénation Mentale. Etudes Psychologiques. Paris: Fortin &amp; Masson; 1845.</p>
<p>Noteboom L. Experimental catatonia by means of derivatives of mescaline and adrenaline. Proc Natl Acad Sci USA 1934; 37: 562–3.</p>
<p>Noyes AP, Kolb LC. Modern Clinical Psychiatry. Philadelphia: W. Saunders; 1958.</p>
<p>Osmond H, Smythies J. Schizophrenia: a new approach. J Ment Sci 1952; 98: 309–15.</p>
<p>Prinzmetal M, Blumberg W. The use of Benzedrine in the treatment of narcolepsy. JAMA 935; 105: 2051–3.</p>
<p>Putnam TJ. The demonstration of the specific anticonvulsant action of diphenylhydantoin and related compounds. In: Ayd FJ, Blackwell B, editors. Discoveries in Biological Psychiatry. Philadelphia: Lippincott; 1970. p. 85–90.</p>
<p>Schneider K. Klinische Psychopathologie. 3 Auflage. Stuttgart: Thieme; 1950.</p>
<p>Sertűrner FW. Darstellung der reinen Mohnsäure (Opiumsäure) nebst einer Chemischen Undersuchung des Opiums mit vorzűglicher Hinsicht auf einen darin neu entdecten stof und dahin gehörigen Bemerkungen. Journal der Pharmacie fűr Ärzten und Apotheken (Leipzig) 1806; 14: 47–93.</p>
<p>Shorter E. A History of Psychiatry. New York: John Wiley; 1997.</p>
<p>Shorter E. Historical Dictionary of Psychiatry. A Oxford: Oxford University Press; 2005.</p>
<p>Stokes JH, Sternberg TH, Schwartz WH, Mahoney JF, Moore JE, Wood WB. The action of penicillin in late syphilis including neurosyphilis. JAMA 1944; 126: 73–9.</p>
<p>Stoll A, Hofmann A. Partial synthese von Alkaloiden Typus des Ergobasins. Helv Chim Acta 1943; 26: 944–7.</p>
<p>Thorner NW. Psychopharmacology of sodium amytal. I. Catatonia. J Nerv Ment Dis 1935; 82: 299–303.</p>
<p>Wernicke C. Lehrbuch der Gehirnkrankheiten. Breslau: Schlettersche Buchhandlung; 1881.</p>
<p>Wimmer A. Psykogene Syndssygdomsformer. Copenhagen: Lunds; 1916.</p>
<p>Wood A. A new method of treating neuralgia by the direct application of opiates to the painful points. Edinb Med and Surg J 1855; 82: 265–81.</p>
<p>&nbsp;</p>
<p>September 6<a name="_GoBack"></a>, 2018</p>
<p>&nbsp;</p>
<p>&nbsp;</p></div><!--DMAILER_SECTION_BOUNDARY_END--><!--TYPO3SEARCH_end--></div>
				</div>
				<div id="ie_clearing">&nbsp;</div>
			</div>
		</div>
		<div id="footer">&copy; INHN 2012-2022 ::: INHN Central Office  · Av. Sagrada Familia Esq Nazaret · Córdoba, Córdoba X5000 · Argentina  ::: email: inhn@inhn.org</div>
	</div>
</div>





<script src="IMAGES/URCHIN.JS" type="text/javascript">
</script>
<script type="text/javascript">
_uacct = "UA-39727086-1";
urchinTracker();
</script>
</body>
</html>